Cassava Sciences | PTIE - Assets


Cassava Sciences reported $100.06M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Abbott USD 108.25B 968M Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cassava Sciences USD 100.06M 3.84M Sep/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Geron USD 527.11M 8.1M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Novavax USD 888M 67.57M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026